120 related articles for article (PubMed ID: 38603831)
1. Acesulfame potassium upregulates PD-L1 in HCC cells by attenuating autophagic degradation.
Kim DH; Kwon EJ; Park KG; Jin J; Byun JK
Biochem Biophys Res Commun; 2024 Jun; 711():149921. PubMed ID: 38603831
[TBL] [Abstract][Full Text] [Related]
2. TP53/mTORC1-mediated bidirectional regulation of PD-L1 modulates immune evasion in hepatocellular carcinoma.
Yu J; Ling S; Hong J; Zhang L; Zhou W; Yin L; Xu S; Que Q; Wu Y; Zhan Q; Bao J; Xu N; Liu Y; Chen K; Wei X; Liu Z; Feng T; Zhou L; Xie H; Wang S; Liu J; Zheng S; Xu X
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38030304
[TBL] [Abstract][Full Text] [Related]
3. Disruption of SIRT7 Increases the Efficacy of Checkpoint Inhibitor via MEF2D Regulation of Programmed Cell Death 1 Ligand 1 in Hepatocellular Carcinoma Cells.
Xiang J; Zhang N; Sun H; Su L; Zhang C; Xu H; Feng J; Wang M; Chen J; Liu L; Shan J; Shen J; Yang Z; Wang G; Zhou H; Prieto J; Ávila MA; Liu C; Qian C
Gastroenterology; 2020 Feb; 158(3):664-678.e24. PubMed ID: 31678303
[TBL] [Abstract][Full Text] [Related]
4. SYVN1 ubiquitinates FoxO1 to induce β-catenin nuclear translocation, PD-L1-mediated metastasis, and immune evasion of hepatocellular carcinoma.
Xie W; Shi L; Quan H; Xiao H; Chen J; Liu J; de Dieu Habimana J; Huang R; Luo J; Chen P; Li Z
Cell Oncol (Dordr); 2023 Oct; 46(5):1285-1299. PubMed ID: 37099251
[TBL] [Abstract][Full Text] [Related]
5. LRPPRC facilitates tumor progression and immune evasion through upregulation of m
Wang H; Tang A; Cui Y; Gong H; Li H
Front Immunol; 2023; 14():1144774. PubMed ID: 37063837
[TBL] [Abstract][Full Text] [Related]
6. IL-6 promotes PD-L1 expression in monocytes and macrophages by decreasing protein tyrosine phosphatase receptor type O expression in human hepatocellular carcinoma.
Zhang W; Liu Y; Yan Z; Yang H; Sun W; Yao Y; Chen Y; Jiang R
J Immunother Cancer; 2020 Jun; 8(1):. PubMed ID: 32581055
[TBL] [Abstract][Full Text] [Related]
7. EZH2 negatively regulates PD-L1 expression in hepatocellular carcinoma.
Xiao G; Jin LL; Liu CQ; Wang YC; Meng YM; Zhou ZG; Chen J; Yu XJ; Zhang YJ; Xu J; Zheng L
J Immunother Cancer; 2019 Nov; 7(1):300. PubMed ID: 31727135
[TBL] [Abstract][Full Text] [Related]
8. KDM1A Promotes Immunosuppression in Hepatocellular Carcinoma by Regulating PD-L1 through Demethylating MEF2D.
Wang Y; Cao K
J Immunol Res; 2021; 2021():9965099. PubMed ID: 34307695
[TBL] [Abstract][Full Text] [Related]
9. Expression of tumor-associated macrophages and PD-L1 in patients with hepatocellular carcinoma and construction of a prognostic model.
Kong P; Yang H; Tong Q; Dong X; Yi MA; Yan D
J Cancer Res Clin Oncol; 2023 Sep; 149(12):10685-10700. PubMed ID: 37306737
[TBL] [Abstract][Full Text] [Related]
10. Lipopolysaccharide facilitates immune escape of hepatocellular carcinoma cells via m6A modification of lncRNA MIR155HG to upregulate PD-L1 expression.
Peng L; Pan B; Zhang X; Wang Z; Qiu J; Wang X; Tang N
Cell Biol Toxicol; 2022 Dec; 38(6):1159-1173. PubMed ID: 35438468
[TBL] [Abstract][Full Text] [Related]
11. IL-6 and PD-L1 blockade combination inhibits hepatocellular carcinoma cancer development in mouse model.
Liu H; Shen J; Lu K
Biochem Biophys Res Commun; 2017 Apr; 486(2):239-244. PubMed ID: 28254435
[TBL] [Abstract][Full Text] [Related]
12. CDK5 destabilizes PD-L1 via chaperon-mediated autophagy to control cancer immune surveillance in hepatocellular carcinoma.
Zhang R; Wang J; Du Y; Yu Z; Wang Y; Jiang Y; Wu Y; Le T; Li Z; Zhang G; Lv L; Ma H
J Immunother Cancer; 2023 Nov; 11(11):. PubMed ID: 38007240
[TBL] [Abstract][Full Text] [Related]
13. Programmed Death Ligand-1 (PD-L1) Regulated by NRF-2/MicroRNA-1 Regulatory Axis Enhances Drug Resistance and Promotes Tumorigenic Properties in Sorafenib-Resistant Hepatoma Cells.
Li D; Sun FF; Wang D; Wang T; Peng JJ; Feng JQ; Li H; Wang C; Zhou DJ; Luo H; Fu ZQ; Zhang T
Oncol Res; 2020 Dec; 28(5):467-481. PubMed ID: 32560747
[TBL] [Abstract][Full Text] [Related]
14. The EGFR-P38 MAPK axis up-regulates PD-L1 through miR-675-5p and down-regulates HLA-ABC via hexokinase-2 in hepatocellular carcinoma cells.
Liu Z; Ning F; Cai Y; Sheng H; Zheng R; Yin X; Lu Z; Su L; Chen X; Zeng C; Wang H; Liu L
Cancer Commun (Lond); 2021 Jan; 41(1):62-78. PubMed ID: 34236149
[TBL] [Abstract][Full Text] [Related]
15. Interferon regulatory factor 1 (IRF-1) and IRF-2 regulate PD-L1 expression in hepatocellular carcinoma (HCC) cells.
Yan Y; Zheng L; Du Q; Yan B; Geller DA
Cancer Immunol Immunother; 2020 Sep; 69(9):1891-1903. PubMed ID: 32377817
[TBL] [Abstract][Full Text] [Related]
16. Knockdown of METTL5 inhibits the Myc pathway to downregulate PD-L1 expression and inhibits immune escape of hepatocellular carcinoma cells.
Xu W; Liu S; Zhang G; Liu J; Cao G
J Chemother; 2023 Sep; 35(5):455-464. PubMed ID: 36369791
[TBL] [Abstract][Full Text] [Related]
17. Immune checkpoint molecules are regulated by transforming growth factor (TGF)-
Shrestha R; Bridle KR; Crawford DHG; Jayachandran A
Int J Med Sci; 2021; 18(12):2466-2479. PubMed ID: 34104078
[TBL] [Abstract][Full Text] [Related]
18. BCLAF1 binds SPOP to stabilize PD-L1 and promotes the development and immune escape of hepatocellular carcinoma.
Yu Z; Wu X; Zhu J; Yan H; Li Y; Zhang H; Zhong Y; Lin M; Ye G; Li X; Jin J; Li K; Wang J; Zhuang H; Lin T; He J; Lu C; Xu Z; Zhang X; Li H; Jin X
Cell Mol Life Sci; 2024 Feb; 81(1):82. PubMed ID: 38340178
[TBL] [Abstract][Full Text] [Related]
19. C-X-C chemokine receptor 2 (Cxcr2) promotes hepatocellular carcinoma immune evasion via regulating programmed death-ligand 1 (PD-L1).
Wan Y; Ge K; Zhou W; Lu J; Jia C; Zhu H
Biol Chem; 2021 May; 402(6):729-737. PubMed ID: 33583159
[TBL] [Abstract][Full Text] [Related]
20. LncTUG1 promotes hepatocellular carcinoma immune evasion via upregulating PD-L1 expression.
Wu R; Liu W; Yang Q; Zhang J; Hou P; Xiong J; Wu L; Li E
Sci Rep; 2023 Oct; 13(1):16998. PubMed ID: 37813900
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]